Hematologic, individual, and cytogenetic data of patients with t(14;19)(q32;q13)
Patient no. . | Sex . | Age, y . | WBC count, × 109/L (% blasts) . | Hb level, g/L . | Platelet count, × 109/L . | Survival . | Immunophenotype . | Karyotype* . |
|---|---|---|---|---|---|---|---|---|
| P1 | F | 7 | 13.4 (92) | 75 | 167 | 12 y | Early pre-B/pre-B?† | 46, XX,t(14;19)(q32;q13)[2]/45,idem,der(16)t (16;17)(q11;q11),–17[14] |
| P2 | F | 26 | 4.5 (55) | 100 | 50 | Unknown | Early pre-B/pre-B?† | 46,XX,dup(1)(q21q31),t(14;19)(q32;q13)[2] |
| P3 | M | 22 | 6.8 (26) | 53 | 17 | 5 mo (d) | Early pre-B (CD10+, Igc–) | 46,XY,t(14;19)(q32;q13)[9] |
| P4 | M | 40 | 4.9 (67) | 55 | 27 | 5 mo (d) | Pro-B (CD10-, Igc-) | 46,XY,t(14;19)(q32;q13)[12]/46,idem,idic(8)(p11)[6] |
| P5 | F | 38 | 16.2 (72) | 104 | 37 | 3 mo | Early pre-B (CD10+, Igc–)‡ | 46,XX,del(7)(p?15),t(14;19)(q32;q13)[20] |
| P6 | M | 76 | 11 (77) | 126 | 57 | 5 mo (d) | Pre-B (CD10–, Igc+) | 46,XY,t(14;19)(q32;q13)[7] |
| P7 | F | 38 | 94 (46) | 120 | 168 | 22 d (d) | Early pre-B (CD10+, Igc–)§ | 46,XX,t(9;22)(q34;q11)[9]/46,idem,i(7)(p10)[2]/47,idem,+8,t(14;19)(q32;q1 3)[8]/48,idem,+6,t(8;9)(q?;q11),+der(22)t(9;22)[21]§ |
| P8 | F | 41 | 1.5 (16) | 82 | 145 | 9 mo | Early pre-B/pre-B?† | 46,XX,t(14;19)(q32;q13)[10] |
Patient no. . | Sex . | Age, y . | WBC count, × 109/L (% blasts) . | Hb level, g/L . | Platelet count, × 109/L . | Survival . | Immunophenotype . | Karyotype* . |
|---|---|---|---|---|---|---|---|---|
| P1 | F | 7 | 13.4 (92) | 75 | 167 | 12 y | Early pre-B/pre-B?† | 46, XX,t(14;19)(q32;q13)[2]/45,idem,der(16)t (16;17)(q11;q11),–17[14] |
| P2 | F | 26 | 4.5 (55) | 100 | 50 | Unknown | Early pre-B/pre-B?† | 46,XX,dup(1)(q21q31),t(14;19)(q32;q13)[2] |
| P3 | M | 22 | 6.8 (26) | 53 | 17 | 5 mo (d) | Early pre-B (CD10+, Igc–) | 46,XY,t(14;19)(q32;q13)[9] |
| P4 | M | 40 | 4.9 (67) | 55 | 27 | 5 mo (d) | Pro-B (CD10-, Igc-) | 46,XY,t(14;19)(q32;q13)[12]/46,idem,idic(8)(p11)[6] |
| P5 | F | 38 | 16.2 (72) | 104 | 37 | 3 mo | Early pre-B (CD10+, Igc–)‡ | 46,XX,del(7)(p?15),t(14;19)(q32;q13)[20] |
| P6 | M | 76 | 11 (77) | 126 | 57 | 5 mo (d) | Pre-B (CD10–, Igc+) | 46,XY,t(14;19)(q32;q13)[7] |
| P7 | F | 38 | 94 (46) | 120 | 168 | 22 d (d) | Early pre-B (CD10+, Igc–)§ | 46,XX,t(9;22)(q34;q11)[9]/46,idem,i(7)(p10)[2]/47,idem,+8,t(14;19)(q32;q1 3)[8]/48,idem,+6,t(8;9)(q?;q11),+der(22)t(9;22)[21]§ |
| P8 | F | 41 | 1.5 (16) | 82 | 145 | 9 mo | Early pre-B/pre-B?† | 46,XX,t(14;19)(q32;q13)[10] |
WBC indicates white blood cell; Hb, hemoglobin; (d), dead; and Igc, cytoplasmic IgM
Normal population omitted from the karyotype
CD10+, Igc not done
All analyzed myeloid markers (myeloperoxidase, CD13, CD33, CD117, CD65) were negative for all patients, except for P5 (CD13+)
All karyotypes were analyzed from bone marrow, except for P7 (peripheral blood)